Author Archives: Gary Mirams

Postdoc position available

Another short post, just to advertise a postdoctoral research associate (PDRA) position available to work with me. It’s a two year position, based at the Centre for Mathematical Medicine & Biology at the University of Nottingham, with the potential to … Continue reading

Posted in Drug action, Experimental Design, Future developments, Ion Channel Models, Model Development, Safety Pharmacology, Stats and Inference | Tagged , , | Leave a comment

CiPA in-silico modelling meeting

There’s an effort underway to evaluate, improve and implement mathematical models of cardiac electrophysiology for pharmaceutical cardiac safety testing and regulatory practice. In particular, to be part of a more mechanistic and accurate in-vitro assessment of pro-arrhythmic risk than the … Continue reading

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology | Tagged , , | Leave a comment

Arrhythmic risk: regression, single cell biophysics, or big tissue simulations?

On the 15th March I presented at an FDA public Advisory Committee hearing on the proposals of the CiPA initative. CiPA aims to replace the current testing for increased drug-induced Torsade de Pointes (TdP) arrhythmic risk, which is a human … Continue reading

Posted in Action Potential Models, Drug action, Future developments, Model Development, Safety Pharmacology, Tissue Simulations | Tagged , , , , , , , | 1 Comment

Uncertainty quantification for ion channel screening and risk prediction

This post accompanies our new paper in Wellcome Open Research. Regular readers of this blog will know that I worry about uncertainty in the numbers we are using to model drug action on electrophysiology quite a lot – see our … Continue reading

Posted in Drug action, Model Development, Safety Pharmacology, Stats and Inference | Tagged , , , , , , , , , | 4 Comments

Ablation, scars and insights from parameter lumping

This is quite a long post elaborating on a bit of work I’ve been doing with Greg Morley and his group, which was published in Scientific Reports. I hope it provides an accessible introduction to a fairly complicated set of experiments … Continue reading

Posted in Action Potential Models, Future developments, Model Development, Tissue Simulations | Tagged , , , , , , , , , , | Leave a comment

Should I work with IC50s or pIC50s?

When you are expressing how much a drug inhibits something, it’s common to fit a Hill curve through a graph of concentration against % inhibition as shown here: In our case this is often ‘% inhibition’ for a given ionic … Continue reading

Posted in Drug action, Safety Pharmacology, Stats and Inference | Tagged , , , , , , , , , , , , | 1 Comment

Is your model really ‘comprehensive’?

I’ve noticed more and more papers using the phrase “comprehensive model”. This phrase grates every time, and this post is about why. I thought this might just be me getting old and grumpy, so I plotted the mentions of the … Continue reading

Posted in Blog, Model Development, Silly | Tagged , , , , , | Leave a comment